CurrentAetnaPolicy 0022

Calcitriol, Etelcalcetide (Parsabiv), and Paricalcitol (Zemplar) Injections

Medical necessity, precertification, indications, continuation, dosing, experimental uses, and coding guidance for calcitriol, etelcalcetide (Parsabiv), and paricalcitol (Zemplar) injections for Aetna commercial medical plans.

Policy Summary

PayerAetna

PolicyCalcitriol, Etelcalcetide (Parsabiv), and Paricalcitol (Zemplar) Injections

Policy CodePolicy 0022

Change TypeNo material clinical or coverage changes

Effective DateApr 24, 1996

Next Review DateDec 12, 2024

Key ActionPrecertification is required for etelcalcetide (Parsabiv) and coverage is limited to members who have failed or are intolerant of specified alternatives.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

RequiredPrecertification

≥8.3 mg/dLParsabiv calcium threshold

2 binders; 2 VDs; 6 mo cinacalcetBrand exception trials

J0636, J2501Covered HCPCS (if criteria met)

SHPT on HDEtelcalcetide indication

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Calcitriol, Paricalcitol, and Etelcalcetide

inv-01: Calcitriol: Initial Therapy

Calcitriol injection is considered medically necessary when ALL of the following are met:

Calcitriol initial approval: Member has hypocalcemia and/or secondary hyperparathyroidism in chronic kidney disease on hemodialysis.

All other indications are experimental, investigational, or unproven.

inv-02: Calcitriol: Continuation Therapy

Continuation of calcitriol is considered medically necessary when ALL of the following are met:

Calcitriol continuation: Member has an indication listed above and is experiencing benefit as evidenced by improvement or stabilization of serum calcium and phosphorus levels and/or a decrease in parathyroid hormone (PTH) from pretreatment baseline.

inv-03: Etelcalcetide (Parsabiv): Initial Therapy

Etelcalcetide (Parsabiv) is considered medically necessary when ALL of the following are met:

Parsabiv initial approval: Member has secondary hyperparathyroidism with chronic kidney disease on hemodialysis AND corrected serum calcium >= 8.3 mg/dL.corrected serum calcium >= 8.3 mg/dL

All other indications considered experimental/investigational.

inv-04: Etelcalcetide (Parsabiv): Continuation Therapy

Continuation of etelcalcetide is considered medically necessary when ALL of the following are met:

Parsabiv continuation: Member requests reauthorization for an indication listed in Section I and is experiencing benefit as evidenced by a decrease in intact parathyroid hormone (iPTH) levels from pretreatment baseline.

inv-05: Paricalcitol (Zemplar): Initial Therapy

Paricalcitol (Zemplar) is considered medically necessary when ALL of the following are met:

Paricalcitol initial approval: Member on hemodialysis with chronic kidney disease requires prevention or treatment of secondary hyperparathyroidism.

All other indications are experimental/investigational.

inv-06: Paricalcitol (Zemplar): Continuation Therapy

Continuation of paricalcitol is considered medically necessary when ALL of the following are met:

Paricalcitol continuation: Member has an indication listed above and is experiencing benefit as evidenced by a decrease in intact parathyroid hormone (iPTH) levels from pretreatment baseline.

inv-07: Coverage for calcitriol and paricalcitol injections (FDA-based clinical criteria)

Covered when ALL of the following are met (implied from FDA indications and text):

Primary renal indications: Patient has end-stage renal disease or chronic kidney disease on dialysis with secondary hyperparathyroidism or hypocalcemia (examples: ICD-10 codes N18.6, N25.81, Z99.2, E83.51).

Based on FDA-approved indications for calcitriol and paricalcitol injections.

Prior therapy or route consideration: Parenteral calcitriol may be used when patients have not responded to oral calcitriol; parenteral therapy is considered when oral therapy is insufficient or not tolerated.

Implied sequencing from product labeling and background.

Contraindications and monitoring: Calcitriol or paricalcitol should not be used in patients with hypercalcemia or vitamin D toxicity; serum calcium and phosphorus should be monitored early during dose adjustment.

Dose adjustments and monitoring per labeling to avoid hypercalcemia.

inv-08: Evidence summary — benefits and risks

Summary of trial-based findings relevant to coverage decisions:

Paricalcitol effects on PTH and proteinuria: Randomized and crossover studies reported that paricalcitol decreased serum PTH and reduced proteinuria in renal transplant recipients and in other small trials (e.g., Trillini et al.; Oblak et al.).

Benefits observed over 6- to 24-week periods in small trials.

Cardiac structural outcomes: Paricalcitol reduced left atrial volume index in a post-hoc analysis (PRIMO) but did not reduce left ventricular mass index in a larger randomized trial (Thadhani et al.).

Mixed cardiac outcomes; clinical significance uncertain.

Safety signals: Paricalcitol therapy was associated with more frequent episodes of hypercalcemia in randomized trials; reductions in eGFR were observed in some studies, necessitating monitoring.

Adverse events may limit use or require laboratory surveillance.

inv-09: Evidence summaries — clinical evidence findings in this segment

Clinical evidence findings summarized in this segment:

IgA nephropathy evidence: Meta-analysis of 7 RCTs (310 Chinese participants) showed calcitriol reduced proteinuria (SMD -1.49) with no significant change in serum creatinine, calcium, or phosphorus; adverse reactions were reported as mild.

Limited population and trial details; suggests potential proteinuria benefit.

Transplant biomarker effects: In a double-blind RCT (n=168) paricalcitol 2 µg/day added to RAS inhibition lowered IL-6 and TGF-β compared with placebo, though the trial was not designed to assess hard clinical outcomes.2 µg/day, 24 weeks

Biomarker improvements require confirmation in trials powered for clinical outcomes.

inv-10: Paricalcitol — transplant and proteinuria findings (randomized trials and secondary analyses)

Summary of clinical evidence from randomized trials and secondary analyses:

Transplant proteinuria and biomarker findings: In randomized trials of kidney transplant recipients with residual proteinuria despite optimized RAS blockade, addition of paricalcitol 2 µg/day for 24 weeks decreased UPCR/UACR/24-hour proteinuria and lowered inflammatory biomarkers IL-6 and TGF-β versus placebo.2 µg/day, 24 weeks

Trials showed reductions in proteinuria and biomarkers but were not powered to demonstrate long-term graft or renal outcomes.

inv-11: Paricalcitol / vitamin D analogs — diabetic nephropathy (systematic reviews and small trials)

Evidence summary from systematic reviews and small trials:

Diabetic nephropathy evidence: Systematic reviews and small randomized studies reported reductions in albuminuria/proteinuria with vitamin D analogs, but trials are few and underpowered; evidence that paricalcitol preserves GFR is lacking and some studies reported increased serum phosphorus or decreased eGFR.clinical trial evidence limited

No compelling evidence of kidney function preservation; caution due to limited data.

inv-12: Paricalcitol / active vitamin D in hemodialysis patients with COVID-19 — observational findings

Observational findings:

HD COVID-19 cohort association: In a retrospective cohort of 288 hemodialysis patients with COVID-19, receipt of active vitamin D medications or calcimimetics (including paricalcitol) was associated with lower mortality in multivariate analysis.observational association

Retrospective design limits causal inference; further prospective studies needed.

inv-13: Paricalcitol in polycystic kidney disease (PKD) — preclinical/animal findings

Preclinical/animal findings:

PKD animal model results: In LPK rat models, paricalcitol alone or with enalapril did not alter kidney enlargement or cyst growth; combination therapy reduced blood pressure and cardiac enlargement but paricalcitol raised serum calcium and reduced body weight.animal model results

Human trials required before clinical application.

inv-14: Paricalcitol for ischemia-reperfusion injury (AKI model) — preclinical findings

Preclinical findings:

Ischemia-reperfusion (AKI) model: In rat ischemia-reperfusion injury models, paricalcitol decreased MMP-2 and MMP-9 expression and reduced tubular injury scores; creatinine fell but not significantly.preclinical evidence

Clinical relevance uncertain; further studies needed.

inv-15: Etelcalcetide (Parsabiv) — approved indication and safety considerations (regulatory and safety summary)

Regulatory and safety summary:

Approved indication: Etelcalcetide (Parsabiv) is FDA-approved for secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis.FDA label

Not studied or recommended for parathyroid carcinoma, primary hyperparathyroidism, or CKD patients not on hemodialysis.

Safety considerations: Contraindications include hypersensitivity to etelcalcetide or excipients; label warnings include hypocalcemia, worsening heart failure, upper GI bleeding, and adynamic bone; common adverse reactions include decreased blood calcium, muscle spasms, nausea, and paresthesia.

Diabetic patients require close monitoring due to hypocalcemia-related cardiac risks and potential interactions with hypoglycemic agents.

inv-16: Use of etelcalcetide (Parsabiv)

Covered when ALL of the following are met

Population and indication: Adult patients with chronic kidney disease on maintenance hemodialysis with secondary hyperparathyroidism.

Based on FDA-approved indication and trial populations; see clinical trials for PTH entry criteria.

Therapeutic intent and administration: IV administration thrice-weekly after each hemodialysis session in accordance with prescribing information and trial protocols.

Trials administered etelcalcetide IV after hemodialysis sessions.

Monitoring and safety documentation: Document baseline and serial PTH and serum calcium monitoring due to risk of hypocalcemia; avoid use in patients with known hypersensitivity to etelcalcetide or its excipients.

Label includes warnings for hypoglycemia, worsening heart failure, GI bleeding, and adynamic bone; monitor diabetic patients closely.

Aetna considers calcitriol and paricalcitol injections experimental, investigational, or unproven for a range of non–chronic kidney disease/hemodialysis indications because safety and effectiveness have not been established. Listed examples include dermatologic conditions (e.g., atopic dermatitis), pulmonary and systemic disorders (e.g., cystic fibrosis), cardiovascular and neurologic conditions (e.g., multiple sclerosis, cerebral ischemia), metabolic or renal conditions outside the dialysis setting (e.g., diabetic nephropathy, non-nephrotic proteinuria indications not specified in the labeled renal indications), and various malignancies (e.g., prostate, pancreatic, and other solid tumors).

Etelcalcetide (Parsabiv) is considered experimental, investigational, or unproven for adult patients with CKD who are not on hemodialysis and for other off‑label endocrine indications such as primary hyperparathyroidism and parathyroid carcinoma. The FDA‑approved label restricts Parsabiv to secondary hyperparathyroidism in adult CKD patients on hemodialysis; use outside that population has not been studied or recommended and is therefore not supported.

Use of calcitriol, paricalcitol, or etelcalcetide for the numerous listed non‑renal diagnoses and for many malignancies is not supported by the evidence in this document. The policy enumerates excluded ICD‑10 ranges and condition examples (for instance, myelodysplastic syndromes, pancreatic and other solid tumors, sepsis, and graft‑versus‑host disease) for which these agents are considered unproven.

A large meta‑analysis of randomized controlled trials found that vitamin D supplementation was not associated with a reduced risk of stroke (24 RCTs, 86,202 participants; pooled RR 1.02, 95% CI 0.93–1.13), and therefore supplementation for the purpose of stroke risk reduction is not supported by high‑quality evidence.

Randomized trial evidence of vitamin D or active vitamin D analogues in chronic liver disease is of very low certainty because most trials were at high risk of bias, small, and underpowered; reported effects on mortality, liver‑related morbidity, and other clinically important outcomes are uncertain, and routine use in chronic liver disease is not supported.

Etelcalcetide (Parsabiv) has not been studied and is not recommended for treatment of parathyroid carcinoma, primary hyperparathyroidism, or for adults with CKD who are not on maintenance hemodialysis. These limitations of use are specified in the FDA labeling and echoed in the policy as unsupported indications.

Use of etelcalcetide in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or CKD not on hemodialysis is not recommended / not studied and is considered experimental or investigational for those populations.

All other indications not explicitly listed in the policy's Initial Approval sections are considered experimental, investigational, or unproven and therefore not medically necessary when used outside the specified, evidence‑based renal indications.

There is no evidence to support the use of calcitriol or paricalcitol as an anti‑tumor or single‑agent therapy for malignancies such as myelodysplastic syndromes or castration‑resistant prostate cancer; small trials reported no objective responses and the agents are not established for oncologic single‑agent treatment.

Across trials of vitamin D supplementation in chronic liver disease, reviewers judged the certainty of evidence to be very low; findings for mortality, liver‑related outcomes, adverse events, and quality of life were inconsistent or imprecise, so no conclusive benefit is demonstrated and routine use is not supported.

Coding Guidance and Billing

Calcitriol HCPCS (covered if criteria met)HCPCSCovered

J0636

Injection, calcitriol, 0.1 mcg

Paricalcitol HCPCS (covered if criteria met)HCPCSCovered

J2501

Injection, paricalcitol, 1 mcg

Related CPT codesCPT

82310 - 82331	Calcium
83970	Parathormone (parathyroid hormone)
84100	Phosphorus inorganic (phosphate)
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular
96379	Unlisted therapeutic, prophylactic, or diagnostic intravenous or intra-arterial injection or infusion

Covered ICD-10 diagnosis codes (if selection criteria met)ICD-10Covered

E83.51	Hypocalcemia
N18.6	End stage renal disease
N25.81	Secondary hyperparathyroidism of renal origin
Z99.2	Dependence on renal dialysis

ICD-10 codes not covered for indications listedICD-10Not Covered

A40.0 - A41.9	Sepsis
C00.0 - D09.9	Malignant neoplasm
E08.21, E09.21, E10.21, E11.21, E13.21	Diabetes mellitus with diabetic nephropathy
E84.0 - E84.9	Cystic fibrosis
G35	Multiple sclerosis

Paricalcitol and related HCPCSHCPCSCovered

J2501	Injection, paricalcitol, 1 mcg
J1270	Injection, doxercalciferol, 1 mcg

Etelcalcetide and related codesHCPCSCovered

J0606	Injection, etelcalcetide, 0.1 mg
J0604	Cinacalcet, oral, 1 mg, (ESRD on dialysis) [not covered for concurrent use with etelcalcetide]

ICD-10 codes covered when selection criteria are metICD-10Covered

N18.6	End stage renal disease
N25.81	Secondary hyperparathyroidism of renal origin
Z99.2	Dependence on renal dialysis
E83.51	Hypocalcemia

ICD-10 codes noted as not covered for CPB indications or otherwise listedICD-10Not Covered

C25.0 - C25.9	Malignant neoplasm of pancreas (listed as not covered for CPB indications)
D46.0 - D46.9	Myelodysplastic syndromes (listed as not covered for CPB indications)
C75.0	Malignant neoplasm of parathyroid gland (not covered)
E21.0	Primary hyperparathyroidism (not covered)
N18.1 - N18.5	Chronic kidney disease (CKD) stages 1-5 (listed in document context)

Corrected serum calcium for Parsabiv initiation — numeric threshold

Corrected serum calcium threshold>= 8.3 mg/dL

ContextRequired prior to Parsabiv initiation, dose increase, or re-initiation after interruption

Source noteThreshold is corrected for albumin per policy appendix

Calcitriol pharmacologic activity duration — 3-5 days

Pharmacologic activity durationApproximately 3–5 days

Prior Authorization, Documentation, and Provider Responsibilities

Prior Authorization

Prior authorization required

Precertification (prior authorization) is required for etelcalcetide (Parsabiv) for applicable Aetna commercial plans. Providers must submit a Statement of Medical Necessity (SMN) or use Specialty Pharmacy precertification processes; call (866) 752-7021 or fax (888) 267-3277 for precertification. Precertification/PA rules apply according to the member’s plan design and do not by themselves guarantee coverage — plan benefits and CPB provisions determine final benefit applicability.

Precertification required for Parsabiv — contact numbers and SMN form instructions
PA determinations depend on plan provisions and CPBs; precertification ≠ coverage guarantee

Documentation Required

Etelcalcetide (Parsabiv) indication verification

Prior authorization must document the FDA‑approved indication for etelcalcetide: secondary hyperparathyroidism (SHPT) in adults with chronic kidney disease on hemodialysis. For Parsabiv, the PA should verify the member is on hemodialysis and has an iPTH baseline consistent with policy thresholds (and serum calcium ≥ 8.3 mg/dL where applicable). Off‑label use (for patients not on hemodialysis, primary HPT, or parathyroid carcinoma) is not recommended and may be denied.

Background and Scope

These agents are used to manage hypocalcemia and secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis. Calcitriol and paricalcitol are active vitamin D receptor activators administered parenterally when oral therapy is insufficient or adherence is a concern; etelcalcetide (Parsabiv) is an IV calcimimetic given at the end of hemodialysis sessions for secondary hyperparathyroidism in adult patients on maintenance hemodialysis.

Definitions and Abbreviations

Secondary hyperparathyroidism (of renal origin) — definition / clinical context

DefinitionElevated parathyroid hormone (PTH) levels occurring in chronic kidney disease, particularly in patients on hemodialysis, leading to disturbances in calcium and phosphorus metabolism

Clinical consequencesContributes to renal osteodystrophy and abnormalities of mineral metabolism

Therapeutic targetsManaged with agents that lower PTH such as calcitriol, paricalcitol, or calcimimetics (e.g., etelcalcetide) in patients on dialysis

Parsabiv (etelcalcetide) administration timing — IV bolus three times/week at dialysis end

Administration timingAdministered by IV bolus three times weekly at the end of each hemodialysis treatment

Missed dose instruction

Revision History and Policy Dates

1996-04-24effective_date

Policy became effective.

2024-02-01last_review

Policy was last reviewed.

2024-12-12next_review_scheduledLatest

Next scheduled review date for the policy.

Policy Summary

PayerAetna

PolicyCalcitriol, Etelcalcetide (Parsabiv), and Paricalcitol (Zemplar) Injections

Policy CodePolicy 0022

Change TypeNo material clinical or coverage changes

Effective DateApr 24, 1996

Next Review DateDec 12, 2024

Key ActionPrecertification is required for etelcalcetide (Parsabiv) and coverage is limited to members who have failed or are intolerant of specified alternatives.

SourceLink

On This Page

Formulation contextApplies to administered calcitriol (injection) with rapid availability in bloodstream after bolus injection

Monitoring implicationMonitor serum calcium and phosphorus during dose adjustment due to prolonged activity

Paricalcitol safety monitoring thresholds — dose decrease if iPTH < 15 pg/ml or serum calcium > 2.60 mM/L

Paricalcitol dose-reduction triggersDecrease dose if intact PTH (iPTH) < 15 pg/mL

Hypercalcemia triggerDecrease dose if serum calcium > 2.60 mM/L

Most actionable safety pointReduce paricalcitol dose when iPTH < 15 pg/mL or serum calcium > 2.60 mM/L to limit adynamic bone and hypercalcemia risk

Enrollment UPCR threshold — UPCR ≥ 20 mg/mM

Enrollment UPCR thresholdUPCR >= 20 mg/mM

Trial contextUsed for enrollment in paricalcitol transplant/proteinuria trials despite optimized RAS blockade

Implication for documentationDocument baseline UPCR when seeking coverage for paricalcitol in similar clinical scenarios

PA must confirm CKD on hemodialysis with SHPT (N18.6, N25.81, Z99.2 as applicable)
Do not request coverage for off‑label populations (CKD not on HD, primary HPT, parathyroid carcinoma)

Documentation Required

PA and documentation for injectable vitamin D analogues

For injectable vitamin D analogues (calcitriol, paricalcitol, doxercalciferol) a prior authorization may be required under applicable plans. When seeking coverage, submit clinically documented indication, prior therapy history, and baseline laboratory results (including serum calcium, phosphorus, and PTH). Providers must show benefit from therapy for continuation requests (improvement or stabilization in calcium/phosphorus and/or reduction in PTH).

Provide baseline and serial labs (serum calcium, phosphorus, intact PTH) with initial and reauthorization requests
Document prior response/benefit for continuation of therapy

Step Therapy

Step therapy / brand exception for Parsabiv

Step‑therapy and brand‑selection requirements apply for Parsabiv: it is considered medically necessary only after contraindication, intolerance, or inadequate response to specified alternatives. The required prior treatment trials include phosphate binders, vitamin D analogs, and cinacalcet as detailed below.

At least 2 phosphate binders tried (each ≥ 2 months)
At least 2 vitamin D analogs tried (each ≥ 2 months)
Therapeutic failure, contraindication, or intolerance to cinacalcet after at least a 6‑month trial at maximum tolerated dose

Step Therapy

Preferred sequencing and consideration of oral cinacalcet

Preferred sequencing is implied: oral therapies (for example, oral calcitriol or cinacalcet) should be tried before switching to parenteral/injectable options when clinically appropriate. Consider an oral cinacalcet trial prior to IV etelcalcetide unless contraindicated or not tolerated; randomized trials compared etelcalcetide with oral cinacalcet and support considering oral therapy first.

Consider trial of oral cinacalcet (J0604) before initiating etelcalcetide unless contraindicated
Injectable therapy appropriate when oral therapy is insufficient, not tolerated, or contraindicated

Billing Rule

Required claim‑level diagnosis and HCPCS linkage

Claims must include appropriate diagnosis and HCPCS linkage to support medical necessity. Use renal and SHPT ICD‑10 codes covered by this CPB and the correct HCPCS for the drug administered. Use of excluded or non‑covered ICD‑10 codes can trigger denial.

Include HCPCS J0606 for etelcalcetide (0.1 mg) when applicable and J0604 (cinacalcet oral) is noted as not covered concurrently
Include covered ICD‑10 codes such as N18.6, N25.81, Z99.2, and E83.51 where applicable
Avoid submitting excluded ICD‑10 codes listed in the CPB to prevent denial

Denial Risk

Concurrent therapy and claim denial risks

Concurrent therapy with oral cinacalcet (J0604) and IV etelcalcetide may lead to denial; do not bill both concurrently. Also be aware of other potential denial triggers when unsupported or excluded diagnosis codes are used on the claim.

Concurrent use/billing of J0604 (cinacalcet oral) with J0606 (etelcalcetide) is not covered and may be denied
Verify diagnosis codes match CPB‑covered indications to avoid denials

Documentation Required

Clinical monitoring and outcome documentation

Monitoring and documentation of laboratory outcomes are expected. Trials and RCTs reported baseline and serial measures of intact PTH, serum calcium, phosphorus, bone markers (e.g., bone‑specific alkaline phosphatase, osteocalcin), and urinary markers (e.g., deoxypyridinoline‑to‑creatinine) to demonstrate response and safety (for example, hypercalcemia events with paricalcitol). Providers should submit relevant baseline and follow‑up lab data to support medical necessity and continuation requests.

Report baseline and serial iPTH, serum calcium, and phosphorus
Include bone markers and urinary markers when available (e.g., bone‑specific alkaline phosphatase, osteocalcin, UPCR, deoxypyridinoline)
Document adverse events such as hypercalcemia, which was more frequent with paricalcitol in trials

Note

Study enrollment and monitoring parameters

Study enrollment criteria and monitoring parameters from clinical trials inform prior authorization expectations: many trials enrolled patients with elevated baseline PTH and required pre‑treatment labs and specified dose adjustments for safety (for example, dose reductions when iPTH suppressed < 15 pg/mL or calcium exceeded thresholds). Use these clinical trial parameters as operational guidance when documenting medical necessity and safety monitoring.

Trials required baseline PTH thresholds and serial monitoring during treatment
Dose adjustments for paricalcitol and etelcalcetide were made for low iPTH or elevated calcium
UPCR and proteinuria criteria were used in transplant paricalcitol trials

Denial Risk

Etelcalcetide safety, contraindications, and diabetes‑related caution

Safety considerations and contraindications for etelcalcetide must be documented. Etelcalcetide is contraindicated in individuals with known hypersensitivity to the drug or its excipients. Label warnings include hypocalcemia, potential worsening heart failure, GI bleeding, adynamic bone, and common adverse reactions such as decreased blood calcium, muscle spasms, nausea, and paresthesia. Diabetic patients on hemodialysis require close monitoring for hypocalcemia and hypoglycemia interactions; avoid concurrent oral hypoglycemics when possible and monitor for cardiovascular events.

Document known hypersensitivity — contraindication to etelcalcetide
Monitor for hypocalcemia and related cardiac risks; exercise caution in diabetic patients and avoid combining with certain oral hypoglycemics/insulins
Record and report adverse reactions and any cardiopulmonary or GI safety concerns

Documentation Required

Provider responsibilities for documentation and medical necessity

Providers are responsible for supplying medical documentation to support medical necessity per the plan. Clinical Policy Bulletins assist in administering plan benefits but do not constitute coverage guarantees or medical advice. Ensure submitted documentation includes indication, prior therapies, baseline and serial labs, and adverse event monitoring to support authorization decisions.

Include documentation of indication, prior treatment trials, and baseline/serial labs with PA requests
CPB is a plan administration aid — final coverage depends on plan benefits and PA determination
Treating providers remain responsible for clinical care and monitoring

Do not give missed doses outside dialysis; resume at end of next dialysis session; if >2 weeks missed, re-initiate at starting dose

Dosing initiation noteEnsure corrected serum calcium is at or above lower limit of normal prior to initiation, dose increase, or re-initiation

Calcitriol — active form of vitamin D3, injectable use when oral insufficient

DefinitionActive form of vitamin D3 (cholecalciferol) used as an anti-hypocalcemic agent; injectable calcitriol suppresses PTH when oral forms are insufficient

Sites of actionActs on intestine, bone, kidney, and parathyroid gland to stimulate intestinal calcium transport

Use caseInjected when patients have not responded to oral calcitriol (e.g., Rocaltrol); monitor calcium/phosphorus closely

Paricalcitol (Zemplar) — synthetic VDRA indicated for SHPT in CKD on dialysis

DefinitionSynthetic, biologically active vitamin D2 analog (paricalcitol, Zemplar) indicated for prevention and treatment of secondary hyperparathyroidism in CKD patients on dialysis

MechanismBinds the vitamin D receptor (VDR) leading to selective activation of vitamin D–responsive pathways and inhibition of PTH synthesis and secretion

Safety noteContraindicated in hypercalcemia and vitamin D toxicity; labeling warns of hypercalcemia, digitalis toxicity, and adynamic bone disease

Vitamin D receptor activator (VDRA) — definition and comparative note

DefinitionAgents that activate the vitamin D receptor (VDR), including calcitriol and paricalcitol

Comparative noteParicalcitol is a selective VDRA with a more favorable calcium/phosphate profile compared to calcitriol

Clinical implicationSelective VDR activation may reduce hypercalcemia risk versus non-selective VDR activators

Left atrial volume index (LAVi) — echocardiographic measure definition

DefinitionEchocardiographic measure of left atrial size indexed to body surface area used to assess diastolic function and predict cardiovascular morbidity

Clinical useReported as an outcome (LAVi) in paricalcitol studies (e.g., PRIMO post-hoc analysis) showing reductions with therapy

Interpretation noteChanges in LAVi may reflect effects on cardiac structure but require confirmation in larger trials

UPCR — urinary protein-to-creatinine ratio; trial enrollment threshold noted elsewhere

DefinitionUrinary protein-to-creatinine ratio (UPCR)

Trial enrollment thresholdUPCR >= 20 mg/mM used as inclusion criterion in paricalcitol transplant/proteinuria trials

Documentation implicationBaseline UPCR should be recorded when considering paricalcitol for residual proteinuria

Non-nephrotic range proteinuria — definition used in IgA nephropathy studies

DefinitionProteinuria below the nephrotic range as defined in IgA nephropathy studies where calcitriol reduced proteinuria

Evidence contextMeta-analysis of 7 RCTs (310 participants) showed calcitriol reduced proteinuria in non-nephrotic IgA nephropathy

Clinical implicationFindings support potential antiproteinuric effect in non-nephrotic range proteinuria but are limited by study populations

Secondary hyperparathyroidism (SHPT) — concise definition and link to Parsabiv indication

Concise definitionElevated PTH in CKD leading to disturbances in mineral metabolism; common complication of CKD and the primary indication for agents like etelcalcetide

Treatment linkSHPT is the FDA-approved indication for etelcalcetide in adults on hemodialysis and is treated with VDRAs or calcimimetics

Clinical monitoringManagement requires monitoring of PTH, serum calcium and phosphorus to avoid over-suppression and hypercalcemia

Etelcalcetide (Parsabiv) — definition as IV calcimimetic approved for SHPT on hemodialysis

DefinitionIntravenous calcimimetic that allosterically modulates the calcium-sensing receptor (CaSR), approved for treatment of SHPT in adult CKD patients on hemodialysis

MechanismBinds CaSR to enhance receptor activation by extracellular calcium, decreasing PTH secretion

Safety/label noteContraindicated in hypersensitivity; warnings include hypocalcemia, worsening heart failure, GI bleeding, adynamic bone; not recommended for breastfeeding

Corrected calcium — formula provided

Corrected calcium formulaCorrected calcium = measured total calcium + 0.8(4.0 - serum albumin)

Use in policyApplied to determine eligibility for Parsabiv initiation and dosing decisions

Measurement implicationEnsure albumin measured concurrently with total calcium to compute corrected calcium